Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies
US9333255B2 · kind B2 · utility
1Cited by
7References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 1, 2013 |
| Grant date | May 10, 2016 |
| Priority date | — |
| Expiry date | Oct 1, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.